Acetyl-l-carnitine as a possible therapy for Alzheimer's disease.

abstract：:Pain is one of the most troublesome sequelae of stroke, occurring in 19-74% of patients. A portion of this post-stroke pain is caused by the brain lesion itself; this is called 'central post-stroke pain' (CPSP). Although the prevalence of CPSP among stroke patients is low (1-8%), the persistent, often treatment-refrac...

journal_title：Expert review of neurotherapeutics

authors： Kim JS

更新日期：2009-05-01 00:00:00

abstract：:Research into what works in depression is in trouble. All treatments appear equally effective and what happens in research trials does not seem to translate into clinical practice or, to put it another way, clinical practice is not reflected in randomized controlled trials. We run the risk of designing cosmetic trials...

journal_title：Expert review of neurotherapeutics

authors： Hatcher S

更新日期：2006-01-01 00:00:00

abstract：:Stroke is the third leading cause of mortality in the USA and one of the leading causes of severe morbidity. It is important to provide stroke patients and physicians with the most accurate prognostic information to optimize care and allocation of healthcare resources. Reliable prognostic markers available during the ...

journal_title：Expert review of neurotherapeutics

authors： Katan M,Elkind MS

更新日期：2011-02-01 00:00:00

abstract：:Translation of the analgesic efficacy of investigational neurotherapeutics from pre-clinical pain models into clinical trial phases is associated with a high risk of failure. Application of human pain biomarkers in early stages of clinical trials can potentially enhance the rate of successful translation, which would ...

journal_title：Expert review of neurotherapeutics

authors： Arendt-Nielsen L,Nielsen TA,Gazerani P

更新日期：2014-03-01 00:00:00

abstract：:Neurostimulation therapy involves the use of peripheral or central nerve electrical stimulation approaches for the treatment of medically intractable headache. Currently, for peripheral stimulation the main approach is that of occipital nerve stimulation, while for central stimulation deep-brain approaches with the ta...

journal_title：Expert review of neurotherapeutics

authors： Goadsby PJ

更新日期：2007-12-01 00:00:00

abstract：:Genetic analysis is providing new information on the biological basis of epilepsy at a rapid pace; this article identifies factors acting as major barriers to use of these data for therapy development. Disease heterogeneity is a primary obstacle since so many genes can cause or predispose to epilepsy and the clinical ...

journal_title：Expert review of neurotherapeutics

authors： Ferraro TN

更新日期：2016-01-01 00:00:00

abstract：:In recent years there has been great scientific and public interest focused on the therapeutic potential of compounds derived from cannabis for the treatment of refractory epilepsy in children. From in vitro and in vivo studies on animal models, cannabidiol (CBD) appears to be a promising anticonvulsant drug with a fa...

journal_title：Expert review of neurotherapeutics

authors： Paolino MC,Ferretti A,Papetti L,Villa MP,Parisi P

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron degeneration in the brain and spinal cord. Treatment development for ALS is complicated by complex underlying disease factors. Areas covered: Numerous tested drug compounds have shown no benefits in ALS p...

journal_title：Expert review of neurotherapeutics

authors： Garbuzova-Davis S,Thomson A,Kurien C,Shytle RD,Sanberg PR

更新日期：2016-12-01 00:00:00

abstract：:Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of β-amyloid peptides and neurofibrilllary tangles in brain, resulting in neuronal death and loss of cognitive abilities. It has been hypothesized that longstanding psychological stress can result in neural degenerat...

journal_title：Expert review of neurotherapeutics

authors： Johansson L

更新日期：2014-02-01 00:00:00

abstract：:Major depression and depressive symptoms are highly prevalent and there is a need for different forms of psychological treatments that can be delivered from a distance at a low cost. In the present review the authors contrast face-to-face and Internet-delivered cognitive behavior therapy (ICBT) for depression. A total...

journal_title：Expert review of neurotherapeutics

authors： Andersson G,Topooco N,Havik O,Nordgreen T

更新日期：2016-01-01 00:00:00

abstract：:Cognitive dysfunction (CD) affects 40-65% of multiple sclerosis (MS) patients and can have a great functional impact. It can be detected in all the disease phenotypes from the early stages of the disease and tends to progress over time. Memory, complex attention, information processing speed and executive functions ar...

journal_title：Expert review of neurotherapeutics

authors： Amato MP,Zipoli V,Portaccio E

更新日期：2008-10-01 00:00:00

abstract：:Neuroprotective therapy has been proposed for age-related neurodegenerative disorders, including Parkinson's disease. Inhibitors of type B monoamine oxidase (MAOB-Is), rasagiline and (-)deprenyl, are the most promising candidate neuroprotective drugs. Clinical trials of rasagiline in patients with Parkinson's disease ...

journal_title：Expert review of neurotherapeutics

authors： Naoi M,Maruyama W

更新日期：2009-08-01 00:00:00

abstract：INTRODUCTION:Neurodegenerative processes occur from the beginning of multiple sclerosis, contribute to irreversible clinical disability and are only partially addressed by current disease-modifying therapies. Reliable quantification of neuro-axonal damage may contribute to improve the assessment of disease activity and...

journal_title：Expert review of neurotherapeutics

authors： Preziosa P,Rocca MA,Filippi M

更新日期：2020-08-01 00:00:00

abstract：:Estrogens fluctuations, particularly their premenstrual fall, are currently regarded as the main triggers of menstrual migraine (MM). MM presents in two clinical forms: pure MM, where attacks are confined to the perimenstrual period (PMP), and menstrually related migraine, where attacks always occur during, but are no...

journal_title：Expert review of neurotherapeutics

authors： Allais G,Castagnoli Gabellari I,De Lorenzo C,Mana O,Benedetto C

更新日期：2007-09-01 00:00:00

abstract：:The kynurenine pathway has received increasing attention as its connection to inflammation, the immune system and neurological conditions has become more apparent. It is the primary route for tryptophan catabolism in the liver and the starting point for the synthesis of nicotinamide adenine dinucleotide in mammals. Dy...

journal_title：Expert review of neurotherapeutics

authors： Davis I,Liu A

更新日期：2015-01-01 00:00:00

abstract：:Glatiramer acetate (GA; Copaxone(®), Teva Pharmaceuticals Inc.), approved in the USA in 1996 and EU in 2001 as first-line treatment for relapsing-remitting multiple sclerosis, is now available in 51 countries and recently gained approval for delaying conversion to clinically definite multiple sclerosis in patients wit...

journal_title：Expert review of neurotherapeutics

authors： Johnson KP

更新日期：2012-04-01 00:00:00

abstract：:Multiple sclerosis (MS) is an autoimmune disorder characterized by CNS inflammation, demyelination and cellular damage with atrophy. Most patients with MS initially present with a relapsing-remitting course, with periodic episodes of neurologic symptomatology that do not follow a predictable pattern. In order to maint...

journal_title：Expert review of neurotherapeutics

authors： Fox EJ

更新日期：2010-12-01 00:00:00

abstract：:Many antiepileptic drugs (AEDs) have therapeutic applications that extend beyond epilepsy to include neuropathic pain, migraine headaches and psychiatric disorders. The risk of some AEDs has been clearly established, but for newer drugs, small sample sizes and polytherapy exposures preclude a conclusive determination ...

journal_title：Expert review of neurotherapeutics

authors： Hill DS,Wlodarczyk BJ,Palacios AM,Finnell RH

更新日期：2010-06-01 00:00:00

abstract：:The term cervicogenic headache (CeH) describes a syndrome originating from the cervical spine. There are a variety of therapeutic approaches used for the management of CeH, but scientific evidence of their effectiveness is scarce. No medication drug has proven to be effective. The evidence for greater occipital nerve ...

journal_title：Expert review of neurotherapeutics

authors： Fernández-de-las-Peñas C,Cuadrado ML

更新日期：2014-01-01 00:00:00

abstract：:Panic disorder is one of the most common anxiety disorders and has a lifetime prevalence of 3-5%. Panic attacks can begin at any age, but commonly have their onset in early adulthood between the ages of 20 and 40 years. Naturalistic data has shown that panic disorder has a chronic and relapsing course. Panic disorder ...

journal_title：Expert review of neurotherapeutics

authors： Dannon PN,Lowengrub K,Iancu I,Kotler M

更新日期：2004-03-01 00:00:00

abstract：:This review will update current views of the physiopathology and treatment of fatigue in multiple sclerosis. Fatigue is a common symptom in multiple sclerosis, being reported by about a third of the patients. For many of them it is the most disabling symptom, with negative consequences on working activity and daily li...

journal_title：Expert review of neurotherapeutics

authors： Comi G,Leocani L

更新日期：2002-11-01 00:00:00

abstract：:The increasing prevalence of chronic pain with its major societal impact and the escalating use of opioids in managing it, along with their misuse, abuse, associated fatalities and costs, are epidemics in modern medicine. Over the past two decades, multiple lessons have been learned addressing various issues of abuse....

journal_title：Expert review of neurotherapeutics

authors： Manchikanti L,Boswell MV,Hirsch JA

更新日期：2013-05-01 00:00:00

abstract：:Acute pain informs the individual that there is an imminent threat of body damage, and is associated with the urge to escape and avoid. Fear learning takes place when neutral stimuli receive the propensity to predict the occurrence of pain, and when defensive responses are initiated in anticipation of potential threat...

journal_title：Expert review of neurotherapeutics

authors： den Hollander M,de Jong JR,Volders S,Goossens ME,Smeets RJ,Vlaeyen JW

更新日期：2010-11-01 00:00:00

abstract：INTRODUCTION:Friedreich ataxia (FRDA) is a progressive, inherited, neurodegenerative disease for which there is currently no cure or approved treatment. FRDA is caused by deficits in the production and expression of frataxin, a protein found in the mitochondria that is most likely responsible for regulating iron-sulfur...

journal_title：Expert review of neurotherapeutics

authors： Strawser C,Schadt K,Hauser L,McCormick A,Wells M,Larkindale J,Lin H,Lynch DR

更新日期：2017-09-01 00:00:00

abstract：INTRODUCTION:Non-convulsive status epilepticus (NCSE) is a complex and diverse condition which is often an under-recognised entity in the intensive care unit. When NCSE is identified the optimal treatment strategy is not always clear. Areas covered: This review is based on a literature review of the key literature in t...

journal_title：Expert review of neurotherapeutics

authors： Kinney MO,Kaplan PW

更新日期：2017-10-01 00:00:00

abstract：INTRODUCTION:Neuromodulation techniques play an increasing role in the treatment of primary headaches. While initially reserved for refractory cases they are now increasingly taken into consideration in earlier treatment phases and in non-refractory situations. One of the main reasons for this paradigm shift is that mo...

journal_title：Expert review of neurotherapeutics

authors： Hoffmann J,May A

更新日期：2019-03-01 00:00:00

abstract：:Tension-type headache (TTH) is the most prevalent of all headaches and also represents one of the most expensive clinical conditions for the health system. Despite the high impact of this disorder and the existence of well-established diagnostic criteria, knowledge about TTH is still quite limited. In most cases in wh...

journal_title：Expert review of neurotherapeutics

authors： Speciali JG,Eckeli AL,Dach F

更新日期：2008-05-01 00:00:00

abstract：INTRODUCTION:The number of people with dementia, including Alzheimer's disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, a...

journal_title：Expert review of neurotherapeutics

authors： Khan A,Corbett A,Ballard C

更新日期：2017-07-01 00:00:00

abstract：INTRODUCTION:Multiple Sclerosis is a chronic inflammatory demyelinating disease that affects 2.5 million people in the world. NEDA (No evidence of disease Activity) -4 is a new concept related to absence of disease activity in the context of MS. It takes into account the following four parameters: relapses; disability ...

journal_title：Expert review of neurotherapeutics

authors： Matta AP,Nascimento OJ,Ferreira AC,Magalhães TN,Benevides TP,Kirmse A,Dib JG,Cal H,Orsini M,Araujo LM

更新日期：2016-11-01 00:00:00

abstract：:Introduction: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that arises as a complication of exposure to dopamine receptor blocking agents. Vesicular monoamine transporter type 2 (VMAT2) inhibitors reduce dyskinesia by decreasing transport of monoamines, including dopamine, into presynaptic vesicles, lea...

journal_title：Expert review of neurotherapeutics

authors： Dorfman BJ,Jimenez-Shahed J

更新日期：2021-01-01 00:00:00